The microRNA let-7b-5p Is Negatively Associated with Inflammation and Disease Severity in Multiple Sclerosis.
Georgia Mandolesi, Francesca Romana Rizzo, Sara Balletta...
https://pubmed.ncbi.nlm.nih.gov/33562569/Actively Recruiting
Led by Neuromed IRCCS · Updated on 2022-10-28
300
Participants Needed
1
Research Sites
56 weeks
Total Duration
This research aims to identify new biomarkers linked to synaptic damage in Multiple Sclerosis MS and to study the mechanisms that contribute to this damage. It involves both prospective and retrospective observation over about five years, analyzing blood and cerebrospinal fluid samples taken for diagnostic reasons. The study includes patients with MS, other chronic neurodegenerative diseases such as Amyotrophic Lateral Sclerosis, Alzheimers disease, Parkinsons disease, and healthy subjects as control groups. Participants undergo procedures including lumbar puncture and blood sampling to measure microRNAs, cytokines, chemokines, growth factors, neuronal damage markers like tau proteins and neurofilaments, mitochondrial markers lactate, and free d-amino acids. The study also evaluates synaptic changes using an ex vivo chimeric model of MS with patch-clamp techniques and conducts genotyping to find gene variants associated with synaptic transmission alterations and clinical parameters. Throughout the study, researchers monitor these biomarkers and genetic factors to predict disease progression and identify potential therapeutic targets. Participants provide samples for various laboratory analyses, including SNPs analysis, and clinical assessments such as the Expanded Disability Status Scale EDSS and disease activity indices. The studys main outcome is to identify predictive biomarkers using the ex vivo model, with secondary goals to find new therapeutic targets for MS.
CONDITIONS
Biomarkers of Synaptic Damage in Multiple Sclerosis
D
Diego Centonze, MD
M
Mario Stampanoni Bassi, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Neuromed IRCCS
Lead Sponsor
IRCCS Multimedica
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Single day
Participants undergo lumbar puncture and blood sample collection for microRNAs quantification, SNPs analysis, and other biomarker assessments.
1 visit (in-person)
Duration - Up to 6 years
Participants are observed to identify predictive biomarkers and study synaptic damage mechanisms related to Multiple Sclerosis.
Visit schedule varies depending on clinical follow-up
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Have more questions? Get in touch with our team for quick support
Georgia Mandolesi, Francesca Romana Rizzo, Sara Balletta...
https://pubmed.ncbi.nlm.nih.gov/33562569/Neuromed IRCCS
Lead Sponsor
IRCCS Multimedica
Collaborating Sponsor